SCHEMBL6487583

SCHEMBL6487583

O=C(Nc1ccc(NCCc2ccccn2)cc1)c1cc(F)ccc1-c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPT P10636 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
GAA P10253 1/20 0.52
NAMPT P43490 2/20 0.48
CTNNB1 P35222 1/20 0.47
TCF7L2 Q9NQB0 1/20 0.47
POLB P06746 1/20 0.46
TSHR P16473 1/20 0.46
PDPK1 O15530 1/20 0.46
GCGR P47871 1/20 0.44
CNR1 P21554 1/20 0.44
ALDH1A1 P00352 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
GRM5 P41594 1/20 0.44
MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497186 0.94 CNR1 (0.53) HTTMEN1KMT2AKDM4EMAPT
SCHEMBL6502209 0.94 CTNNB1 (0.50) HTTMEN1KMT2AKDM4EMAPT
SCHEMBL6490335 0.93 CNR1 (0.52) HTTMEN1KMT2AKDM4EMAPT
SCHEMBL6491719 0.92 SMO (0.53) HTTMEN1KMT2AKDM4EMAPT
SCHEMBL6490637 0.92 CTNNB1 (0.54) HTTMEN1KMT2AKDM4EMAPT
SCHEMBL6792583 0.92 KMT2A (0.56) HTTMEN1KMT2AKDM4EMAPT
SCHEMBL6487331 0.90 MEN1 (0.49) HTTMEN1KMT2AKDM4EMAPT
SCHEMBL6501945 0.90 NPC1 (0.56) HTTMEN1KMT2AKDM4EMAPT
SCHEMBL6489333 0.90 TAS1R3 (0.53) HTTMEN1KMT2AKDM4EMAPT
SCHEMBL6490703 0.90 NPC1 (0.48) HTTMEN1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HTT 2574/4885MEN1 1991/4885KMT2A 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.